PRINCETON, N.J. (August 25, 2020) – Otsuka America Pharmaceutical, Inc., (Otsuka) today announces that it has purchased the assets of Proteus Digital Health, Inc. (Proteus), including assets and intellectual property for its ingestible and wearable sensor technology.
This milestone in the evolution of Otsuka’s digital medicine program strengthens its research and product development plan for a next-generation digital medicine that supports patient wellness, treatment decisions and the connections between patients and their healthcare teams.
“The purchase of Proteus assets and intellectual property will serve as a catalyst for implementing the next phase of our digital medicine program,” stated Kabir Nath, president and CEO, Otsuka North America Pharmaceutical Business, Otsuka America, Inc. “More than ever before, Otsuka remains committed to building a best-in-class digital healthcare business that includes both digital medicine and digital therapeutics.”

About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. 
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. 
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ approximately 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology and cardiology, using cutting-edge technology to address unmet healthcare needs. Otsuka’s most recently approved product in the U.S. is the first-ever treatment for autosomal dominant polycystic kidney disease, a genetic disorder in which fluid-filled cysts develop in the kidneys over time, often leading to kidney failure.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13 billion in 2019.
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/.

OAPI Office Contact Information
3956 Point Eden Way
Hayward, CA 94545
T: 800-562-3974